ACY-001 (Compass Biomedical)

N/A

Report date: 2022/07/19 16:22:54

Base Information

Drug NameACY-001 (Compass Biomedical)

Drug Alias NameAutologous CD133 + HSC (critical limb ischemia) therapy, Compass BiomedicalAutologous CD133 + HSC (critical limb ischemia) therapy, ArteriocyteAutologous CD133+ HSC (ischemic heart disease) therapy, ArteriocyteAutologous CD133+ hematopoietic stem cells (ischemic heart disease) therapy, ArteriocyteACY-001

ClassificationCell and gene therapy > Cell therapy > Stem cell therapy

Mechanisms of ActionCell replacementsAngiogenesis inducers

TargetsNot applicable

Therapy Area/IndicationsCoronary Occlusion

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Phase 1 Clinical)

Highest Status in ChinaN/A

Originator CompaniesCompass Biomedical

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesCase Western Reserve University

Active IndicationsN/A

Inactive IndicationsCoronary Occlusion

Other Information

ATC CodeN/A